This site is intended for healthcare professionals

Speciality hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 10th Jul 2020

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Learning Zones

Anticoagulation Therapy for Stroke Prevention

Learning Zone Homepage

Anticoagulation Therapy for Stroke Prevention

COMT inhibition in Parkinson’s Disease

Learning Zone Homepage

COMT inhibition in Parkinson’s Disease

Spinal Muscular Atrophy

Learning Zone Homepage

Spinal Muscular Atrophy

Neuroscience and Pain Learning Zone

Learning Zone Homepage

Neuroscience and Pain Learning Zone

Related news and insights

FDA accepts an sNDA for Brilinta for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.-AstraZeneca .

AstraZeneca announced the FDA has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack (TIA).

1 mins

BIIB 037 filed with FDA for Alzheimer’s disease.- Biogen

Biogen has completed the submission of a Biologics License Application (BLA) to the FDA for the approval of BIIB 037 (aducanumab) an investigational treatment for Alzheimer’s disease.

1 min

Health Canada approves Kynmobi for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease .- Sunovion

Sunovion Pharmaceuticals Inc. announced on 15 June 2020 hat Health Canada has approved Kynmobi (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa.

1 min

See all news

Related drugs

Solpadeine Plus Tablets

Solpadeine Plus Tablets

Solpadeine Plus Capsules

Solpadeine Plus Capsules

solpadeine max tablets

solpadeine max tablets

Paramol Tablets

Paramol Tablets

Paracodol tablets

Paracodol tablets

Paracetamol 500mg Tablets (P)

Paracetamol 500mg Tablets (P)

Paracetamol 500mg Suppositories

Paracetamol 500mg Suppositories

Paracetamol 500mg Soluble Tablets

Paracetamol 500mg Soluble Tablets

Paracetamol 500 mg Caplets

Paracetamol 500 mg Caplets

Paracetamol 250mg/5ml Oral Suspension

Paracetamol 250mg/5ml Oral Suspension

Paracetamol 250mg Suppositories

Paracetamol 250mg Suppositories

Paracetamol 250 mg/5 ml Oral Suspension PL 04917/0029)

Paracetamol 250 mg/5 ml Oral Suspension PL 04917/0029)

Paracetamol 125mg Suppositories

Paracetamol 125mg Suppositories

Paracetamol 120mg/5ml Oral Suspension

Paracetamol 120mg/5ml Oral Suspension

Related Guidelines

Cannabis-based medicinal products

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

1 mins

Risk reduction and management of delirium

This guideline provides recommendations based on current evidence for best practice in the detection, assessment, treatment and follow up of adults with delirium, as well as reducing the risk of delirium.

1 min

Pharmacological management of migraine

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache.

1 min

See all guidelines

Your peers are looking at...

Positive effect of reltecimod on resolution of organ dysfunction in phase III ACCUTE trial for patients with necrotizing soft tissue infection .- Atox Bio

Positive effect of reltecimod on resolution of organ dysfunction in phase III ACCUTE trial for patients with necrotizing soft tissue infection .- Atox Bio

1 mins

Idorsia Ltd announces positive results in the second phase III study of daridorexant in patients with insomnia.

Idorsia Ltd announces positive results in the second phase III study of daridorexant in patients with insomnia.

1 mins

Global survey of COPD in younger and older patients is published in COPD: Journal of Chronic Obstructive Pulmonary Disease.- Boehringer

Global survey of COPD in younger and older patients is published in COPD: Journal of Chronic Obstructive Pulmonary Disease.- Boehringer

2 mins

Hologic launches in the US the SuperSonic™ MACH 40 ultrasound system.

Hologic launches in the US the SuperSonic™ MACH 40 ultrasound system.

1 mins

Leo Pharma files at FDA a BLA for
tralokinumab to treat moderate-to-severe atopic dermatitis.

Leo Pharma files at FDA a BLA for tralokinumab to treat moderate-to-severe atopic dermatitis.

1 mins

Phase III ASCENT study of Trodelvy met its primary endpoint of progression-free survival for triple negative breast cancer.- Immunomedics Inc.

Phase III ASCENT study of Trodelvy met its primary endpoint of progression-free survival for triple negative breast cancer.- Immunomedics Inc.

1 mins

FDA approves Upneeq to treat blepharoptosis. - Osmotica Pharma

FDA approves Upneeq to treat blepharoptosis. - Osmotica Pharma

1 mins

FDA letter sent to Verrica Pharma notes deficiencies in the NDA for VP 102 to treat molluscum contagiosum.

FDA letter sent to Verrica Pharma notes deficiencies in the NDA for VP 102 to treat molluscum contagiosum.

1 mins

FDA approves sBLA for Botox in pediatric patients with lower limb spasticity caused by cerebral palsy.- Allergan/AbbVie

FDA approves sBLA for Botox in pediatric patients with lower limb spasticity caused by cerebral palsy.- Allergan/AbbVie

1 mins

Phase III study FIDELIO-DKD of BAY 94 8862 meets primary endpoint in diabetic kidney disease.- Bayer

Phase III study FIDELIO-DKD of BAY 94 8862 meets primary endpoint in diabetic kidney disease.- Bayer

1 mins

Related Journals

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A Systematic Review and Meta-Analysis.

1 mins

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

1 mins

Emergency Management of Epilepsy and Seizures.

Emergency Management of Epilepsy and Seizures.

1 mins

Executive function in eating disorders: The role of state anxiety

Executive function in eating disorders: The role of state anxiety

1 mins

Alemtuzumab depletion failure can occur in multiple sclerosis.

Alemtuzumab depletion failure can occur in multiple sclerosis.

1 mins

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.

1 mins

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.

1 mins

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

1 mins

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

1 mins

How do Migraines Impact Patient Day-To-Day life? An Exploratory Analysis of Patient Reported Data From The Patientslikeme Community

How do Migraines Impact Patient Day-To-Day life? An Exploratory Analysis of Patient Reported Data From The Patientslikeme Community

1 mins

Related Events

BNA 2021 Festival Of Neuroscience

BNA 2021 Festival Of Neuroscience

European Neurosurgery 2021

European Neurosurgery 2021

World Congress for Brain Mapping and Therapeutics of SBMT 2021 (SBMT 2021)

World Congress for Brain Mapping and Therapeutics of SBMT 2021 (SBMT 2021)

Related Clinical Trials

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

3 mins

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

3 mins

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

3 mins

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

4 mins

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT)

3 mins

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures

3 mins

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

1 mins

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

2 mins

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

2 mins

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

3 mins

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

3 mins

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

4 mins